You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Comparison of the basic and clinical characteristics of patients not treated with MTX (Group 1), treated with MTX by intramuscular injection (Group 2) or treated with MTX by intravenous injection (Group 3)

From: Management of Caesarean scar pregnancy with or without methotrexate before curettage: human chorionic gonadotropin trends and patient outcomes

  Mean ± SD/Rate P value
Group 1(n = 47) Group 2(n = 46) Group 3(n = 14)  
Age (years) 32.04 ± 6.283 31.15 ± 5.597 34.14 ± 4.865 0.206
Previous cesarean section (n) 1.17 ± 0.380 1.17 ± 0.383 1.57 ± 0.514 0.004
Gravidity (n) 4.13 ± 1.24 4.20 ± 1.470 5.0 ± 1.519 0.186
Parity (n) 1.21 ± 0.414 1.22 ± 0.513 1.50 ± 0.519 0.08
Gestational age at diagnosis (days) 52.68 ± 11.66 48.76 ± 8.945 52.15 ± 13.619 0.292
Fetal heart beat positive, n (%) 15(31.9%) 21(45.7%) 5(35.7%) 0.466